Keith Syson Chan
Overview
Explore the profile of Keith Syson Chan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
1838
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rohena-Rivera K, You S, Kim M, Billet S, Hoeve J, Gonzales G, et al.
JCI Insight
. 2024 Nov;
9(24).
PMID: 39509334
Chemotherapy is often combined with surgery for muscle invasive and nonmuscle invasive bladder cancer (BCa). However, 70% of the patients recur within 5 years. Metabolic reprogramming is an emerging hallmark...
2.
Neeli P, Maza P, Chai D, Zhao D, Hoi X, Chan K, et al.
NPJ Vaccines
. 2024 Oct;
9(1):180.
PMID: 39353958
Multiple myeloma (MM), a hematological malignancy of the bone marrow, remains largely incurable. The orphan G protein-coupled receptor, GPRC5D, which is uniquely expressed in plasma cells and highly expressed in...
3.
Ranganathan S, Riveros C, Xu J, Hu S, Geng M, Huang E, et al.
Urol Oncol
. 2024 May;
42(9):291.e13-291.e25.
PMID: 38763801
Introduction: First-line systemic therapy for metastatic urothelial carcinoma of the bladder (mUC) consists of platinum-based chemotherapy in most patients and PD1/L1 inhibitors in selected patients. Multiple combination chemoimmunotherapy trials failed...
4.
Broz M, Ko E, Ishaya K, Xiao J, De Simone M, Hoi X, et al.
Nat Commun
. 2024 Mar;
15(1):2498.
PMID: 38509063
T cell-based immunotherapies have exhibited promising outcomes in tumor control; however, their efficacy is limited in immune-excluded tumors. Cancer-associated fibroblasts (CAFs) play a pivotal role in shaping the tumor microenvironment...
5.
Riveros C, Ranganathan S, Haque W, Huang E, Xu J, Kulkarni G, et al.
Can Urol Assoc J
. 2023 Nov;
18(2):17-24.
PMID: 37931278
Introduction: Elective pelvic nodal irradiation for patients with muscle-invasive bladder cancer (MIBC) undergoing trimodal therapy (TMT ) is controversial. In patients with node-negative (N0) MIBC, the benefit of elective whole-pelvis...
6.
Piras R, Ko E, Barrett C, De Simone M, Lin X, Broz M, et al.
Nat Commun
. 2022 Nov;
13(1):7243.
PMID: 36433954
Exonic circular RNAs (circRNAs) produce predominantly non-coding RNA species that have been recently profiled in many tumors. However, their functional contribution to cancer progression is still poorly understood. Here, we...
7.
You S, Kim M, Hoi X, Lee Y, Wang L, Spetzler D, et al.
J Natl Cancer Inst
. 2022 Aug;
114(10):1380-1391.
PMID: 35918812
Background: Anti-programmed cell death 1 (anti-PD-1) and PD ligand 1 (PD-L1) immune checkpoint therapies (ICTs) provided durable responses only in a subset of cancer patients. Thus, biomarkers are needed to...
8.
Lee Y, Lam H, Rosser C, Theodorescu D, Parks W, Chan K
Nat Rev Urol
. 2022 Jun;
19(9):515-533.
PMID: 35764795
Bladder cancer is a prevalent but currently understudied cancer type and patient outcomes are poor when it progresses to the muscle-invasive stage. Current research in bladder cancer focuses on the...
9.
Blair A, Wang J, Davelaar J, Baker A, Li K, Niu N, et al.
Gastroenterology
. 2022 Jun;
163(5):1267-1280.e7.
PMID: 35718227
Background & Aims: The stroma in pancreatic ductal adenocarcinoma (PDAC) contributes to its immunosuppressive nature and therapeutic resistance. Herein we sought to modify signaling and enhance immunotherapy efficacy by targeting...
10.
Nikolos F, Hayashi K, Hoi X, Alonzo M, Mo Q, Kasabyan A, et al.
Nat Commun
. 2022 Mar;
13(1):1487.
PMID: 35347124
Chemoimmunotherapy has recently failed to demonstrate significant clinical benefit in advanced bladder cancer patients; and the mechanism(s) underlying such suboptimal response remain elusive. To date, most studies have focused on...